A novel vaccine based on SARS-CoV-2 CD4 ⁺ and CD8 ⁺ T cell conserved epitopes from variants Alpha to Omicron.

Autor: Palatnik-de-Sousa I; Department of Electrical Engeneering, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, Brazil., Wallace ZS; Department of Informatics, J. Craig Venter Institute, La Jolla, CA, USA.; Department of Computer Science and Engineering, University of California, San Diego, CA, USA., Cavalcante SC; Department of General Microbiology, Institute of Microbiology Paulo de Góes, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Ribeiro MPF; Department of General Microbiology, Institute of Microbiology Paulo de Góes, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Silva JABM; Department of General Microbiology, Institute of Microbiology Paulo de Góes, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Cavalcante RC; Department of Pharmacy, Campus Professor Antônio Garcia Filho, Federal University of Sergipe, Lagarto, Sergipe, Brazil., Scheuermann RH; Department of Informatics, J. Craig Venter Institute, La Jolla, CA, USA.; Department of Pathology, University of California, San Diego, CA, USA.; Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA.; Global Virus Network, Baltimore, MD, USA., Palatnik-de-Sousa CB; Department of General Microbiology, Institute of Microbiology Paulo de Góes, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. immgcpa@micro.ufrj.br.; Institute for Immunological Investigation (III), INCT, National Council for Scientific and Technological Development (CNPq), São Paulo, Brazil. immgcpa@micro.ufrj.br.

Publikováno v: Scientific reports [Sci Rep] 2022 Oct 06; Vol. 12 (1), pp. 16731. Date of Electronic Publication: 2022 Oct 06.